- Home
- BHE vs VKTX Comparison
BHE vs VKTX Comparison
Compare BHE & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BHE | VKTX |
|---|---|---|
| Founded | 1979 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.3B |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BHE | VKTX |
|---|---|---|
| Price | $82.44 | $38.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $55.00 | ★ $95.86 |
| AVG Volume (30 Days) | 552.2K | ★ 3.0M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $2,659,108,000.00 | N/A |
| Revenue This Year | $7.03 | N/A |
| Revenue Next Year | $6.57 | N/A |
| P/E Ratio | $229.17 | ★ N/A |
| Revenue Growth | ★ 0.11 | N/A |
| 52 Week Low | $34.44 | $22.96 |
| 52 Week High | $100.41 | $43.15 |
Technical Indicators
Market Signals| Indicator | BHE | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.55 | 57.20 |
| Support Level | $79.59 | $28.80 |
| Resistance Level | $88.27 | $39.78 |
| Average True Range (ATR) | 4.62 | 2.46 |
| MACD | -1.45 | -0.02 |
| Stochastic Oscillator | 20.96 | 40.34 |
Price Performance
Historical ComparisonAbout BHE Benchmark Electronics Inc.
Benchmark Electronics Inc is engaged in product designing, engineering services, technology solutions, and manufacturing services (electronic manufacturing services (EMS) and precision technology services). It serves various industries, including aerospace & defense (A&D), medical technologies, complex industrials, semiconductor capital equipment, next-generation telecommunications, and high-end computing. Its geographical segments are the Americas, Asia, and Europe, of which key revenue is derived from the Americas.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.